[go: up one dir, main page]

AR017858A1 - Derivados de acido fenilaminoalquilcarboxilico utiles como estimulantes de los beta3-adrenoceptores, composicion farmaceutica, estimulante de losbeta3-adrenoceptores, usos en la fabricacion de medicamentos y procedimiento de fabricacion - Google Patents

Derivados de acido fenilaminoalquilcarboxilico utiles como estimulantes de los beta3-adrenoceptores, composicion farmaceutica, estimulante de losbeta3-adrenoceptores, usos en la fabricacion de medicamentos y procedimiento de fabricacion

Info

Publication number
AR017858A1
AR017858A1 ARP980106341A ARP980106341A AR017858A1 AR 017858 A1 AR017858 A1 AR 017858A1 AR P980106341 A ARP980106341 A AR P980106341A AR P980106341 A ARP980106341 A AR P980106341A AR 017858 A1 AR017858 A1 AR 017858A1
Authority
AR
Argentina
Prior art keywords
group
adrenoceptors
atom
derivatives
manufacture
Prior art date
Application number
ARP980106341A
Other languages
English (en)
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of AR017858A1 publication Critical patent/AR017858A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Derivados de ácido fenilaminoalquilcarboxílico representado por la formula general (I), (donde R1 representa un grupo hidroxi, un grupo alcoxi inferior, ungrupo aralcoxi, un grupo amino, un grupo amino alicíclico o un grupo mono- o di- (alquil inferior)amino, que puede tener un grupo hidroxi o un grupo alcoxiinferior como substituyente; R2 representa un grupo hidroxi o un grupo alquilo inferior; R3 representa un átomo de hidrogeno o un átomo de halogeno; R4 y R5son iguales o diferentes y cada uno representa átomo de hidrogeno, un átomo de halogeno o un grupo alquilo inferior; A representa un grupo alquileno inferior;el átomo de C marcado con (R) representa un átomo de C en configuracion (R), y el átomo de C marcado con (S) representa un átomo de C en configuracion (S)) ouna sal farmacéuticamente aceptable del mismo, que tiene un excelente efecto estimulante de los beta3-adrenoceptores y es util como agente para la prevencion otratamiento de la obesidad, la hiperglicemia, las enfermedades causadas por hipermotilidad intestinal, la polaquiuria, la incontinencia urinaria, la depresiono las enfermedades causadas por cálculos biliares o hipermotilidad del tracto biliar. Composicion farmacéutica y estimulante que incluye dichos derivados. Unagente para tratamiento de enfermedades. Usos de dichos derivados en la fabricacion de medicamentos. Procedimiento para la fabricacion de una composicionfarmacéutica que comprende la utilizacion como constituyente esencial de dicha composicion farmacéutica de dicho derivado o una sal farmacéuticamente aceptabledel mismo.
ARP980106341A 1997-12-18 1998-12-15 Derivados de acido fenilaminoalquilcarboxilico utiles como estimulantes de los beta3-adrenoceptores, composicion farmaceutica, estimulante de losbeta3-adrenoceptores, usos en la fabricacion de medicamentos y procedimiento de fabricacion AR017858A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP37008797 1997-12-18

Publications (1)

Publication Number Publication Date
AR017858A1 true AR017858A1 (es) 2001-10-24

Family

ID=18496040

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106341A AR017858A1 (es) 1997-12-18 1998-12-15 Derivados de acido fenilaminoalquilcarboxilico utiles como estimulantes de los beta3-adrenoceptores, composicion farmaceutica, estimulante de losbeta3-adrenoceptores, usos en la fabricacion de medicamentos y procedimiento de fabricacion

Country Status (23)

Country Link
US (1) US6353025B1 (es)
EP (1) EP1043308B1 (es)
JP (1) JP4156799B2 (es)
KR (1) KR100545474B1 (es)
AR (1) AR017858A1 (es)
AT (1) ATE250570T1 (es)
AU (1) AU754317B2 (es)
CA (1) CA2315235C (es)
CO (1) CO5070654A1 (es)
CZ (1) CZ296433B6 (es)
DE (1) DE69818516T2 (es)
ES (1) ES2209226T3 (es)
HU (1) HUP0100102A3 (es)
IL (1) IL136612A (es)
MY (1) MY120466A (es)
NO (1) NO20003105L (es)
NZ (1) NZ505103A (es)
PE (1) PE20000131A1 (es)
PL (1) PL341221A1 (es)
SA (1) SA99191012B1 (es)
TW (1) TW503229B (es)
WO (1) WO1999031045A1 (es)
ZA (1) ZA9811655B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138994A (en) * 1998-04-14 2004-02-19 Kissei Pharmaceutical 2-methylpropionic acid derivatives and medicinal compositions containing the same
AU2710301A (en) * 2000-01-28 2001-08-07 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
BR0316080A (pt) * 2002-11-07 2005-09-27 Astellas Pharma Inc Remédio para bexiga superativa compreendendo derivado de ácido acético anildo como o ingrediente ativo
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
WO2004106283A1 (ja) * 2003-05-28 2004-12-09 Kissei Pharmaceutical Co., Ltd. アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
EP1765812B1 (en) 2004-07-02 2009-04-29 Bracco Imaging S.p.A Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
CA2737349A1 (en) 2008-10-09 2010-04-09 Asahi Kasei Pharma Corporation Indazole derivatives
WO2010041569A1 (ja) 2008-10-09 2010-04-15 旭化成ファーマ株式会社 インダゾール化合物
US20100222404A1 (en) * 2008-11-04 2010-09-02 Asahi Kasei Pharma Corporation Indazole derivative dihydrochloride
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146638A (en) * 1976-02-17 1979-03-27 Boehringer Ingelheim Gmbh N-(3-phenoxy-2-hydroxy-propyl)-n-(2-phenyl-2-hydroxy-ethyl)-amines
EP0068669A1 (en) 1981-06-20 1983-01-05 Beecham Group Plc Secondary phenylethanol amines, processes for their preparation and their pharmaceutical application
DE3368258D1 (en) 1982-07-16 1987-01-22 Beecham Group Plc 2-aminoethyl ether derivatives, processes for their preparation and pharmaceutical compositions containing them
ZA835126B (en) * 1982-07-16 1984-06-27 Beecham Group Plc Secondary amines
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds

Also Published As

Publication number Publication date
AU1506199A (en) 1999-07-05
HUP0100102A2 (hu) 2001-05-28
DE69818516T2 (de) 2004-07-08
US6353025B1 (en) 2002-03-05
EP1043308B1 (en) 2003-09-24
ES2209226T3 (es) 2004-06-16
NZ505103A (en) 2003-03-28
PE20000131A1 (es) 2000-03-15
KR20010024747A (ko) 2001-03-26
CA2315235A1 (en) 1999-06-24
CZ296433B6 (cs) 2006-03-15
IL136612A (en) 2003-11-23
ZA9811655B (en) 1999-06-23
TW503229B (en) 2002-09-21
CO5070654A1 (es) 2001-08-28
ATE250570T1 (de) 2003-10-15
HUP0100102A3 (en) 2002-11-28
AU754317B2 (en) 2002-11-14
EP1043308A1 (en) 2000-10-11
SA99191012B1 (ar) 2006-07-03
KR100545474B1 (ko) 2006-01-24
DE69818516D1 (de) 2003-10-30
CZ20002244A3 (cs) 2000-11-15
IL136612A0 (en) 2001-06-14
NO20003105D0 (no) 2000-06-16
EP1043308A4 (en) 2001-11-14
PL341221A1 (en) 2001-03-26
WO1999031045A1 (en) 1999-06-24
JP4156799B2 (ja) 2008-09-24
CA2315235C (en) 2009-07-28
NO20003105L (no) 2000-08-17
MY120466A (en) 2005-10-31

Similar Documents

Publication Publication Date Title
AR017858A1 (es) Derivados de acido fenilaminoalquilcarboxilico utiles como estimulantes de los beta3-adrenoceptores, composicion farmaceutica, estimulante de losbeta3-adrenoceptores, usos en la fabricacion de medicamentos y procedimiento de fabricacion
AR029600A1 (es) Un derivado del acido fenoxiacetico, una composicion farmaceutica que lo contiene y agente util para la prevencion de enfermedades, uso de un derivado del acido fenoxiacetico para la fabricacion de una composicion farmaceutica para los tratamientos de dichas enfermedades y el procedimiento de fabric
BR0209271A (pt) Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
PT1158973E (pt) Utilizacao de derivados de sulfamato para o tratamento dos disturbios do controlo de impulsos
BR0308816A (pt) Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
CO5550436A2 (es) Derivados de benzamida
BR9707606B1 (pt) ácidos 8-ciano-1-ciclopropil-7-(2,8-diazabiciclo(4.3.0) nonan-8-il)-6-flúor-1,4-diidro-4-oxo-3-quinolinocarbo xìlicos, bem como medicamentos que os compreendem.
AR033367A1 (es) Derivados de imidazopirimidina y derivados de triazolopirimidina, un procedimiento para su preparacion, medicamentos, una composicion farmaceutica, y uso de dichos derivados para la preparacion de medicamentos
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
PA8432901A1 (es) Compuestos de piridilpirrol
MY108541A (en) Purine derivatives and use thereof in therapy.
ES2089782T3 (es) Imidazolalquilo sustituido con un anillo heterociclico que contiene nitrogeno de seis elementos.
BRPI0312882B8 (pt) derivados de pleuromutilina e composição farmacêutica
BR0012610A (pt) Novo derivado de difenilpiperidina
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
DE602004015406D1 (de) Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
AR046705A1 (es) Pirido-7-pirimidin-7-onas substituidas con hidroxialquilo
AR035750A1 (es) Uso de n- (piridinilamino) indoles para la preparacion de medicamentos para el tratamiento de enfermedades o trastornos desmielinizantes
IT1317048B1 (it) Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie
BR0318533A (pt) azolidinacarbonitrilas e seu uso como inibidores de dpp-iv
AR015761A1 (es) Un derivado del acido 2-metilpropionico,una composicion farmaceutica que lo incluye, uso de un derivado del acido 2-metilpropionico y un procedimiento parala fabricacion de una composicion farmaceutica para la prevencion o el tratamiento de enfermedades
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
AR018077A1 (es) Empleo de derivados de pirrolidina y piperidina, procedimiento para la preparacion de dichos derivados y medicamento que los contiene
KR890009391A (ko) 무좀 치료제
SE0004462D0 (sv) Novel method and use

Legal Events

Date Code Title Description
FB Suspension of granting procedure